

Minutes: Steering Board meeting, 11 December 2020

1. Update on the allocation of doses [REDACTED] and implementation of contracts

The Members were reminded about the importance of submitting the Order forms **in due time**.

The Commission offered again support to the MSs on the **logistics** aspects.

Moderna :

- the [REDACTED] for Moderna has a new **column on resale/donation** due to many requests from third countries caused by COVAX difficulties to secure doses;
- the Commission will organize a meeting with the representatives of the company and the SB members to explain elements related to medical information, logistics, regulatory aspects etc;
- the Allocation should be sent to Moderna next week;
- the Template Order Forms will be circulated to the SB next week.

Pfizer/BioNTech :

- the MSs were informed that Pfizer [REDACTED];
- furthermore, Members were informed that the company intended [REDACTED];
- the Members also voiced [REDACTED].
- the company provided the **provisional monthly delivery schedule**, which will be circulated to the Members;

2. Update on contracts in the [REDACTED] and discussions with other companies

Novavax - the Members were informed on key elements of the envisaged contract (price, upfront payment, delivery schedule, etc). The Commission is likely to complete the exploratory discussions and the negotiating team will go into the [REDACTED] shortly.

Valneva - preliminary discussions were completed for structure of the envisaged contract, price, delivery and payment schedules and options. [REDACTED] to be sent most probably after New Year.

[REDACTED] - discussions with the company had been completed. Steering Members should instruct negotiating team on desire to take up negotiations with this company.

█ whilst a number of exploratory discussions had taken place, the company was considering its strategy in the light of recent developments, and no firm offer was expected any time soon.

3. Vaccination proof

The Commission presented the proposal for a **single vaccine identifies** with minimal data sets. The approach was centred on health and was not linked to any use that such proof of vaccination could have.

Some MSs took the floor to support of this idea.

One MS highlighted (i) that several MSs were already working on certificates, (ii) the need to assess feasibility vs current stage of developments and (iii) wished to receive details.

4. COVAX

The Commission debriefed the Members on the first meeting of the **subgroup on donations** that discussed technical arrangements on how to organise reselling and donation from the supply side.

During this meeting it was outlined that:

- COVAX remained the main instrument for access to vaccines for low, medium income countries;
- donations in kind were not meant to replace COVAX but bridge the gap until COVAX was in the position to supply in Q2 of next year;
- EU may be sharing a part of its vaccines purchased jointly through APAs at the same time they are delivered here, as an expression of solidarity;
- the aim was not to █, but rather a temporary arrangement sharing vaccines at the same time and until COVAX delivers.
- a list of 3 priority groups was established:

- 1) █
█
█
█.

During the meeting, there was a consensus on a **concept note** proposed by one MS.

The next meeting will go through the practical arrangements and discuss the way forward.